Navigation Links
DiaCarta Inc. Launches QClamp™ Somatic Mutation Real-Time PCR Tests for KRAS, NRAS, EGFR, BRAF, PIK3CA and More Without DNA Extractions
Date:10/28/2013

Hayward, California (PRWEB) October 28, 2013

DiaCarta is a new Translational Genomics and Molecular Diagnostics company located in the San Francisco Bay area and is pioneering novel molecular diagnostics technologies for detection of cancer biomarkers in human body fluids including saliva, blood and urine - so called 'Liquid Biopsy' in the field of Oncology, today announced it has launched its QClamp™ somatic mutation tests, highly sensitive and rapid tests for KRAS, NRAS, EGFR, BRAF, PIK3CA and more in 2 hours without DNA extraction.

QClamp™ is a revolutionary new way to screen for somatic mutations, which utilizes a sequence specific wild-type template xeno-nucleic acid "Clamp" (XNA) that suppresses PCR amplification of wild-type template DNA and allows selective PCR amplification of only mutant templates. This allows the detection of mutant DNA in the presence of a large excess of wild-type template from any type of sample including FFPE, needle biopsy, whole blood and urine. The tests take less than 2 hours from start to finish without DNA extraction using special Qzol direct PCR lysis buffer and can detect below 0.1% mutated DNA.

“Recent studies have demonstrated that DNA sequencing is one of the least sensitive methods for characterizing mutation with only 10-20% of mutated DNA detected,” said Dr. Michael Powell, CSO of DiaCarta. “It has become clear that most if not all tumors are polyclonal and heterogeneous. Consequently, tumor driver mutations may not be detectable using standard DNA sequencing methods. Our QClamp™ tests are super sensitive and rapid. You don’t need to invest hundreds of thousands of dollar for a fancy digital PCR or sequencing machine. Our tests can be run on all currently available real-time PCR machines and everything to perform the tests is included in the kits.” 

“We are very excited to launch this new product line to meet the unmet market,” said Dr. Aiguo Zhang, founder and CEO of DiaCarta. “We have received overwhelming responses from the field and our tests are the best in the market to address the issues with somatic mutation testing in oncology personalized diagnostics. We are in the process of CE Mark applications and expect to receive them by end of this year.”
 
About DiaCarta Inc.
DiaCarta, based in Hayward, Calif., is developing and commercializing in vitro diagnostics for a wide range of diseases based on branched DNA (bDNA) Signal Amplification technology and QClampTM, proprietary technology platforms for gene quantitation and somatic mutation tests. DiaCarta offers a suit of oncogene test and companion diagnostic development services including QuatniVirus® HPVE6/E7 mRNA for cervical cancer and QuantiVirus® HPV E6/E7 mRNA for head-neck cancer tests.

For more information, please contact:
DiaCarta INC
information(at)diacarta.(dot)com
510-314-8858
http://www.diacarta.com

Read the full story at http://www.prweb.com/releases/2013/10/prweb11272188.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. DiaCarta Inc. Receives CE Mark for QuantiVirus® HPV E6/E7 mRNA Assay
2. KEW Group Launches CancerPlex(SM) Assay to Bring State-of-the-Art Genomic Testing to Community Oncologists
3. Cyndy Nayer Launches Center of Health Engagement
4. NextCODE Health Launches Operations with Exclusive License to Leverage deCODE genetics Genomics Platform for Sequence-Based Clinical Diagnostics, and $15 Million in Venture Financing
5. Pipette.com Launches New Blog Solutions.Pipette.com to Help Scientists Find Liquid Handling Answers
6. UE LifeSciences Launches WeMustTry.com Crowdfunding Campaign for Low-cost, Painless Breast Cancer Screening Services Focused on Developing Countries
7. ActiGraph Launches New Generation of Bluetooth® Smart Activity Monitors
8. KromaTiD Launches dGH Chromatid-specific Assays
9. MO BIO Laboratories, Inc. launches a new kit for rapid release of microbial DNA from swabs for PCR analysis
10. Portal Solutions Launches AuthentiMate™ a “Bring Your Own SharePoint Identity” Solution
11. Ventana launches first fully automated IHC test to detect BRAF V600E mutation in a variety of cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, ... viscous and elastic characteristics when deformed, which is identical to how the human ... absorb compressive forces and return to its natural state along a hysteresis curve, ...
(Date:3/23/2017)... 2017  SeraCare Life Sciences, Inc., a manufacturer ... diagnostics manufacturers and clinical laboratories, is announcing ... Inherited Cancer reference material for ... sequencing (NGS). The Seraseq™ Inherited Cancer DNA Mix ... industry experts to validate the ability of ...
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
Breaking Biology Technology:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant ... At PTE ... March, Materna will present its complete end-to-end passenger journey, ... real benefit for passengers. To accelerate the whole passenger handling ... solutions to take passengers through the complete integrated process with ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
Breaking Biology News(10 mins):